ATLANTIS trial: Results for patients treated within 3 hours of stroke onset

Gregory W. Albers, Wayne M. Clark, Kenneth P. Madden, Scott A. Hamilton

Research output: Contribution to journalArticlepeer-review

200 Scopus citations


Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

Original languageEnglish (US)
Pages (from-to)493-495
Number of pages3
Issue number2
StatePublished - 2002


  • Stroke, acute
  • Thrombolysis
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'ATLANTIS trial: Results for patients treated within 3 hours of stroke onset'. Together they form a unique fingerprint.

Cite this